L.A. Zvenigorodskaya –
D. Sc. (Med.), Professor, Leading Research Scientist, Endocrinology Service of the Moscow Clinical Scientific Center n.a. А.S Loginov of the Moscow City Health Department
A.E. Lychkova –
D. Sc. (Med.), Head of Department of Moscow Clinical Scientific Center n.a. А.S Loginov of the Moscow City Health Department
E-mail address: lychkova@mail.ru

According to forecasts of the World Health Organization, non-alcoholic fatty liver disease (NAFLD) by 2020 will occupy the 1st place among all liver diseases. The pathogenetic links of the type 2 diabetes and NAFLD are insulin resistance, lipid metabolism disorders and chronic, subclinical inflammation. The implementation of these pathogenetic mechanisms is carried out primarily at the level of the hepatocyte. NAFLD is a predictor of severe cardiovascular complications, multiple polytopic drug resistance, creates difficulties in the effective treatment of not only type 2 diabetes, but also many other diseases.

Proinflammatory cytokines, interleukins-6 and -8 and tumor necrosis factor α (TNF-α), play an important role in the development of NAFLD. TNF-α is a multifunctional pro-inflammatory cytokine, secreted mainly by macrophages, predominantly adipose tissue, and has auto-and paracrine effects.

The drug Proluent is sutable for the long-term treatment of adult patients with primary hypercholesterolemia (non-family and heterozygous familial hypercholesterolemia) or mixed dyslipidemia, including patients with DM 2, Apo B, TG and LP (a) and increasing concentrations of HDL-C and Apo A-1.

A new, highly effective method for the treatment and prevention of type 2 diabetes, NAFLD and CVD may be the use of monoclonal antibodies – inhibitors of subtilin / kexin type 9 covertase proprotein (PCSK9) – low density lipoprotein receptors.

PCSK9 binds to LDL receptors (R-LDL) on the surface of hepatocytes, contributing to the degradation of R-LDL in the liver. Inhibiting the binding of PCSK9 to R-LDL, alirocumab increases the amount of R-LDL to remove LDL, thus reducing the concentration of Xc-LDL in the blood. Alirocumab also reduces the concentration of lipoproteins (Lp (a)), which are an independent factor for cardiovascular risks.

In in vitro studies, alirocumab did not induce antibody-dependent cell-mediated toxicity and complement-dependent cytotoxicity (Fc-mediated effector function), both in the presence and absence of PCSK9. In alirocumab bound to PCSK9, there was no formation of insoluble immune complexes capable of binding complement proteins.DM 2 and NAFLD – tandem of consistently developing events, have the same type of pathogenetic roots. The metabolic effects of this tandem are responsible for the development of severe cardiovascular diseases.

1. European Association for the Study of the Liver (EASL). European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASLEASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease // J. Hepatol. 2016. V. 64 (6). P. 1388–402.
2. Charlton M.R., Burns J.M., Pederson R.A. et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States // Gastroenterology. 2011. V. 141. P. 1249–53.
3. Hussein O. et al. Orlistat reverse fatty infiltration and improves hepatic fibrosis in obese patients with nonalcoholic steatohepatitis (NASH) // Digestive diseases and sciences. 2007. V. 20. № 10. P. 2512–9.
4. Yalamanchili K., Saadeh S., Klintman G.B. et al. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease // Liver Transplant 2010. V. 16. P. 431–9.
5. Solga S.F., Diehl A. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics // J. Hepatol. 2003. V. 38. P. 681–7.
6. Parnell J.A., Raman M., Rioux K.P., Reimer R.A. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance // Liver Int. 2012. V. 32. P. 701–11.
7. Fang S., Suh J.M., Reilly S.M. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance // Nat. Med. 2015. V. 21 (2). P. 159–65.
8. Brunzell J.D., Ayyobi A.F. Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus // Am. J. Med. 2003. V. 115 (Suppl 8A). P. 24S–28S.
9. Burt A.D., Mutton A., Day C.P. Diagnosis and interpretation of steatosis and steatohepatitis // Semin Diagh Pathol. 1998. V. 4. P. 246–58.
10. Drapkina O.M., Gacolaeva D.S., Ivashkin V.T. Nealkogol'naya zhirovaya bolezn' pecheni kak komponent metabolicheskogo sindroma // Roscijskie medicinskie vesti. 2010. № 2. S. 72–81.
11. Zvenigorodskaya L.A. Organy pishchevareniya i ateroskleroz. M.: Medpraktika-M. 2011. S. 149–76.
12. Nozaki Y., Fujita K., Yoneda M. et al. Long-term combination therapy of ezetimibe and acarbose for nonalcoholic fatty liver disease // J. Hepatol. 2009. V. 51. P. 548–56.
13. Park H., Shima T., Yamaguchi K. et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease // J. Gastroenterol. 2011. V. 46. P. 101–7.
14. Loomba R., Sirlin C.B., Ang B. et al. Ezetimibe for the treatment of nonalcoholic steatohepatitis: assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial) // Hepatology. 2015. V. 61 (4). P. 1239–50.
15. Ivashkin V.T., Drapkina O.M., Maev I.V. i dr. Rasprostranennost' nealkogol'noj zhirovoj bolezni pecheni u pacientov ambulatorno-poliklinicheskoj praktiki v RF: rezul'taty issledovaniya DIREG 2 // Rocsijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2015. T. 6. S. 31–41.
16. Athyros V. et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis // Lancet. 2010. V. 376 (9756). P. 1916–22.
17. Younossi Z.M., Koenig A.B., Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease – Meta-analytic assessment of prevalence, incidence, and outcomes // Hepatology. 2016. V. 64 (1). P. 73–84.
18. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J. et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial // Lancet. 2015. V. 385 (9972). P. 956–65.
19. Fang S., Suh J.M., Reilly S.M. et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance // Nat. Med. 2015. V. 21 (2). P. 159–65.
20. Haukeland J.W., Konopski Z., Eggesbo H.B. et al. Metformin in patients with nonalcoholic fatty liver disease: A randomized, controlled trial // Scand. J. Gastroenterol. 2009. V. 44. P. 853–60.
21. Zhang Z.J., Zheng Z.J., Shi R. et al. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis // J. Clin. Endocrinol. Metab. 2012. V. 97 (7). P. 2347–53.
22. Sanyal A.J. et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis // Clinical Gastroenterology and Hepatology. 2004. V. 2. P. 1107–15.
23. Xiang Z., Chen Y.P., Ma K.F. et al. The role of ursodeoxycholic acid in nonalcoholic steatohepatitis: a systematic review // BMC Gastroenterol. 2013. V. 13. P. 140.
24. Ratziu V., de Ledinghen V., Oberti F. et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis //
    J. Hepatol. 2011. V. 54 (5). P. 1011–19.
25. Hallsworth K., Fattakova G., Hollingsworth K.G. et al. Resistance exercise reduces liver fat and its mediators in nonalcoholic fatty liver disease independent of weight loss // Gut. 2011. V. 60. P. 1278–83.
26. Houghton D., Thoma C., Hallsworth K. et al. Exercise Reduces Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a Randomized Controlled Trial // Clin. Gastroenterol. Hepatol. 2016.  Aug 10 [Epub ahead of print].
27. Ivashkin V.T. YAdernye receptory v patologii pecheni // Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii. 2010. T. 4. S. 7–15.
28. Bueverov A.O., Bogomolov P.O., Maevskaya M.V. Patogeneticheskoe lechenie nealkogol'nogo steatogepatita: obosnovanie, effektivnost', bezopasnost' // Terapevticheskij arhiv. 2007. T. 79 (8). S. 1–4.
29. Seshasai S.R.K., Kaptoge S., Thompson A. et al. Emerging Risk Factors Collaboration, Diabetes mellitus, fasting glucose, and risk of cause-specific death // N. Engl. J. Med. 2011. V. 364. P. 829–41.
30. Targher G., Bertolini L., Rodella S. et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients // Diabetes care. 2007. V. 30(8). P. 2119–2121.
31. Younossi Z.M., Gramlich T., Matteoni C.A. et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes // Clin. Gastro. Hepatol. 2004.
    V. 2(3). P. 262–265.
32. Mantovani A., Ballestri S., Lonardo A., Targher G. Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease // Dig. Dis. Sci. 2016. V. 61(5). P. 1246–1267.
33. Konrad R.J, Troutt J.S., Cao G. Effects of currently prescribed LDL-Clowering drugs on PCSK9 and implications for the next generation of LDLC-lowering agents // Lipids. Health. Dis. 2011. V. 10. P. 38.
34. Koren M.J., Giugliano R.P., Raal F.J. et al. Efficacy and safety of longerterm administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the open-label study of longterm evaluation against LDL-C (OSLER) randomized trial // Circulation. 2014.
    V. 129 (2). P. 234–43.
35. Koren M.J., Lundqvist P., Bolognese M. et al. Anti-PCSK9 monotherapy for hypercholesterolemia – the MENDEL-2 randomized,controlled phase 3 clinical trial of evolocumab // J. Am. Coll. Cardiol. 2014.  № 63(23). P. 2531–40.
36. Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L., Cohen J.C., Hobbs H.H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol // Am. J. Hum. Gen. 2006. V. 78(3). P. 410–422.
37. Benjannet S., Rhainds D., Essalmani R. et al. NARC-1/PCSK9 and Its natural mutants: Zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol // J. Biol. Chem. 2004. V. 279. P. 48865–75.
38. Benn M., Nordestgaard B.G., Grande P. et al. PCSK9 R46L, lowdensity lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses // J. Am. Coll. Cardiol. 2010. № 55. P. 2833–42.
39. Berthold H.K., Seidah N.G., Benjannet S., Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels // PloS One. 2013. V. 8. P. 60095.
40. Blanchet M., Le Q. T. et al. Statins can exert dual, concentration dependent effects on HCV entry in vitro // Antivir Res. 2016. V. 128. P. 43–48.
41. Bridge S.H., Sheridan D.A., Felmlee D.J. et al. PCSK9, apolipoprotein E and lipoviral particles in chronic hepatitis C genotype 3: evidence for genotype-specific regulation of lipoprotein metabolism // J. Hepatol. 2015. V. 6. P. 763–770.
42. Cui Q., Ju X., Yang T. et al. Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis. 2010. V. 213 (2). P. 632–636.
43. Dadu R.T., Ballantyne C.M. Lipid lowering with PCSK9 inhibitors // Nat. Rev. Cardiol. 2014. V. 84. P. 1–13.
44. Davignon J., Dubuc G., Seidah N.G. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis // Curr. Atheroscler. Rep. 2010. V. 12. P. 308–15.
45. Zvenigorodskaya L.A. Nealkogol'naya zhirovaya bolezn' pecheni: evolyuciya predstavlenij, patogeneticheskie akcenty, podhody k terapii // Trudnyj pacient. 2015. № 10–11. S. 37–43.
46. Registracionnoe udostoverenie 16.01.2017. Preparat alirokumab.
47. Leiter, Lawrence A. et al. Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial // Diabetes, Obesity and Metabolism. 2017. V. 19 (12). P. 1781–1792.